RNA - Atrium Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$25.00
DETAILS
HIGH:
$25.00
LOW:
$25.00
MEDIAN:
$25.00
CONSENSUS:
$25.00
UPSIDE:
90.99%
| Metric | 2025 |
|---|---|
| Revenue | |
| Revenue | 18.6 |
| Cost of Revenue | 0 |
| Gross Profit | 18.6 |
| Operating Expenses | |
| R&D Expenses | 53.8 |
| SG&A Expenses | 41.7 |
| Other Expenses | 0 |
| Operating Expenses | 95.4 |
| Operating Income | |
| Operating Income | (76.8) |
| Interest Expense | 0 |
| Interest Income | 0 |
| Profitability | |
| EBITDA | (76.5) |
| EBIT | (76.8) |
| Income Before Tax | (76.8) |
| Income Tax Expense | (0.1) |
| Net Income | (76.7) |
| Per Share Data | |
| EPS (Basic) | -4.48 |
| EPS (Diluted) | -4.48 |
| Shares Outstanding | 17.1 |
| Metric | 2025 |
|---|---|
| Current Assets | |
| Cash & Cash Equivalents | 270 |
| Short-Term Investments | 0 |
| Net Receivables | 0 |
| Inventory | 0 |
| Other Current Assets | 1.3 |
| Total Current Assets | 272.8 |
| Non-Current Assets | |
| Property, Plant & Equipment | 5.5 |
| Goodwill | 0 |
| Intangible Assets | 0 |
| Long-Term Investments | 0 |
| Other Non-Current Assets | 0 |
| Total Non-Current Assets | 5.5 |
| Total Assets | 278.4 |
| Current Liabilities | |
| Account Payables | 4.4 |
| Short-Term Debt | 0 |
| Deferred Revenue | 21.6 |
| Other Current Liabilities | 3.1 |
| Total Current Liabilities | 41.8 |
| Non-Current Liabilities | |
| Long-Term Debt | 0 |
| Deferred Tax Liabilities | 0 |
| Other Non-Current Liabilities | 0.6 |
| Total Non-Current Liabilities | 29.3 |
| Total Liabilities | 71.1 |
| Stockholders' Equity | |
| Common Stock | 0.0 |
| Retained Earnings | 0 |
| Accumulated Other Comprehensive Income | 0 |
| Total Stockholders' Equity | 207.3 |
| Total Liabilities & Equity | 278.4 |
| Debt Metrics | |
| Total Debt | 3.7 |
| Net Debt | (266.3) |
| Metric | 2025 |
|---|---|
| Operating Activities | |
| Net Income | (49.5) |
| Depreciation & Amortization | 0.3 |
| Stock-Based Compensation | 7.7 |
| Change in Working Capital | (0.2) |
| Other Non-Cash Items | 0.7 |
| Operating Cash Flow | (41.1) |
| Investing Activities | |
| Capital Expenditure | (1.4) |
| Acquisitions | 0 |
| Purchases of Investments | 0 |
| Sales/Maturities of Investments | 0 |
| Other Investing Activities | 0 |
| Investing Cash Flow | (1.4) |
| Financing Activities | |
| Net Debt Issuance | 0 |
| Stock Repurchased | 0 |
| Dividends Paid | 0 |
| Other Financing Activities | 42.6 |
| Financing Cash Flow | 42.6 |
| Cash Position | |
| Net Change in Cash | 0 |
| Cash at Beginning | 0 |
| Cash at End | 0 |
| Free Cash Flow | (42.6) |
| Key Metrics | 2025 |
|---|---|
| Income Statement | |
| Revenue | 18.6 |
| Gross Profit | 18.6 |
| Operating Income | (76.8) |
| Net Income | (76.7) |
| EPS (Diluted) | -4.48 |
| Balance Sheet | |
| Cash & Equivalents | 270 |
| Total Assets | 278.4 |
| Total Debt | 3.7 |
| Stockholders' Equity | 207.3 |
| Cash Flow | |
| Operating Cash Flow | (41.1) |
| Capital Expenditure | (1.4) |
| Free Cash Flow | (42.6) |